Many cancers harbor oncogenic mutations of KRAS. Effectors mediating cancer progression, invasion, and metastasis in KRAS-mutated cancers are only incompletely understood. Here we identify cancer cell-expressed murine TRAIL-R, whose main function ascribed so far has been the induction of apoptosis as a crucial mediator of KRAS-driven cancer progression, invasion, and metastasis and in vivo Rac-1 activation. Cancer cell-restricted genetic ablation of murine TRAIL-R in autochthonous KRAS-driven models of nonsmall-cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) reduces tumor growth, blunts metastasis, and prolongs survival by inhibiting cancer cell-autonomous migration, proliferation, and invasion. Consistent with this, high TRAIL-R2 expression correlates with invasion of human PDAC into lymph vessels and with shortened metastasis-free survival of KRAS-mutated colorectal cancer patients.
INTRODUCTION
Twenty-one percent of all human cancers bear oncogenic mutations in KRAS (Bos, 1989) , and their frequency is highest in some of the most aggressive cancers, such as 95% of pancreatic ductal adenocarcinoma (PDAC) (Hidalgo, 2010; Jaffee et al., 2002) , 50% of colorectal adenocarcinoma (Grady and Markowitz, 2002) , and 30% of non-small-cell lung cancers (NSCLCs) (Mitsuuchi and Testa, 2002) . Whereas direct therapeutic targeting of mutated KRAS G12C has recently been achieved (Ostrem et al., 2013) , cancers driven by all other forms of oncogenic KRAS remain difficult to treat. Many effector pathways downstream of KRAS have been implicated in KRAS-driven tumor development and maintenance (Castellano et al., 2013; Downward, 2008; Engelman et al., 2008; Gupta et al., 2007; Ling et al., 2012) . Therefore, small molecule inhibitors targeting these pathways have been developed (Baines et al., 2011) . Their recent clinical application has, however, highlighted that many of these inhibitors activate resistance-causing feedback mechanisms and give cause for concern over toxicity in the clinic. TNF-related apoptosis-inducing ligand (TRAIL, also known as Apo2L) can selectively kill tumor cells in vivo (Ashkenazi et al., 1999; Walczak et al., 1999) . These findings have initiated the development of TRAIL and other TRAIL-receptor (TRAIL-R) agonists for cancer therapy (reviewed in Lemke et al., 2014) . Many tumor cell lines and primary tumors are, however, resistant to TRAIL-induced apoptosis (Koschny et al., 2007; Todaro et al., 2008) . In addition, TRAIL also has been shown to activate nonapoptotic signaling pathways in cancer cell lines such as nuclear factor-kB (NF-kB) (Degli-Esposti et al., 1997; Ehrhardt et al., 2003; Harper et al., 2001; Ishimura et al., 2006; Varfolomeev et al., 2005) , the mitogen-activated kinases (MAPKs) JNK, p38 (Varfolomeev et al., 2005) , and ERK (Belyanskaya et al., 2008) , as well as the kinase Src (Azijli et al., 2012) . These adverse effects were confirmed to be relevant in vivo as therapeutic TRAIL administration promoted liver metastasis of xenotransplanted PDAC (Trauzold et al., 2006) and KRAS-mutated colorectal cancer (CRC) cell lines (Hoogwater et al., 2010) .
Whereas these findings have highlighted potential adverse effects of TRAIL as a single agent therapy, the basic biological question as to why cancer cells would retain TRAIL-R expression if they were resistant to apoptosis induction by TRAIL remained unresolved.
We hypothesized that the endogenous TRAIL/TRAIL-R system might play a role in promoting apoptosis-resistant cancers, which could provide an explanation for the seemingly counterintuitive high expression of TRAIL-Rs and TRAIL in many types of cancer (Elrod et al., 2010; Ganten et al., 2009; Macher-Goeppinger et al., 2009; Ozawa et al., 2001; Sanlioglu et al., 2007) , including NSCLC in which high TRAIL-R2 expression positively correlated with increased risk of death (Spierings et al., 2003) . Therefore, we set out to interrogate the role of cancer cell-expressed TRAIL-Rs in KRAS-driven cancer.
RESULTS
Cancer Cell-Expressed mTRAIL-R Promotes Autochthonous KRAS-Driven Lung Cancer and Formation of Pancreatic Intraepithelial Neoplasia We started our investigation using a variant of the KP murine NSCLC model (Jackson et al., 2001) in which oncogenic KRAS G12D and p53 R172H are expressed from their respective endogenous loci upon adenoviral-Cre (Ad-Cre) infection to give rise to lung tumors that closely resemble human NSCLC (Kasinski and Slack, 2012) . Unlike humans, mice express only one deathdomain (DD)-containing TRAIL-R, mTRAIL-R (MK/mDR5), which is homologous to both human TRAIL-R1 and TRAIL-R2 (Wu et al., 1999) . To interrogate the role of mTRAIL-R in NSCLC, we crossed conditional mTRAIL-R knockout (KO) mice (Grosse-Wilde et al., 2008) with KP mice and induced lung tumors by Ad-Cre infection. Genetic ablation of mTRAIL-R in cancer cells substantially reduced lung tumor size ( Figure 1A ) and weight ( Figure 1B ) in age-matched groups (mTRAIL-R deletion within the largest tumor nodule per lung was confirmed; data not shown). Importantly, reduced lung tumor burden in mTRAIL-R-ablated lungs translated into significantly prolonged survival after tumor initiation ( Figure 1C ). Although the incidence of KRAS mutations is relatively high among NSCLC (30%), it is even higher in PDAC (95%) (Hidalgo, 2010; Jaffee et al., 2002) , which also overexpresses TRAIL-Rs (Ozawa et al., 2001 ). Thus, we next determined the role of mTRAIL-R in the initiation of pancreatic cancer. To this end, we made use of Kras
G12D
;PDX-1-Cre (KC) mice, in which oncogenic KRAS G12D expression is initiated via Cre-recombinase expressed from the PDX-1 promoter leading to mosaic expression of Crerecombinase and the development of pancreatic intraepithelial neoplasia (PanIN) (Hingorani et al., 2003) . Pancreata of agematched KC mice crossed to conditional mTRAIL-R KO mice were macroscopically normal, albeit slightly smaller than KCmTRAIL-R WT pancreata ( Figure 1D ). Importantly, cancer cellspecific absence of mTRAIL-R markedly reduced the number of PanINs that developed in these mice (KC-mTRAIL-R FL/FL ) as compared with littermate controls (KC-mTRAIL-R WT/WT ) (Figure 1E) . The presence of PanINs was confirmed by inspecting sections stained for the epithelial marker CK19, commonly used to distinguish PanINs from normal tissue ( Figure 1F ). Together, these results demonstrate that cancer cell-expressed mTRAIL-R promotes KRAS-driven NSCLC and PanIN formation. (A) A549 shControl, shTRAIL-R1, and shTRAIL-R2 were subjected to soft agar colony formation assays. Relative colony formation was determined normalized to A549-luc pLKO.1 after 4 weeks. (B) KRAS-mutated Panc Tu I, A549-luc and DLD-1 cells were subjected to control or TRAIL-R2 KD for 72 hr and then BrdU proliferation assays.
(C) Six KRAS-mutated and five KRAS-WT cell lines were transfected with siRNAs silencing TRAIL-R2 or mTRAIL-R and subsequently subjected to migration assays. Migration was normalized to control transfected cells in each of the cell lines.
(D) KRAS-mutated cells as in (C) apart from H460 and KRAS-WT cells as in (C) were transfected with siRNAs silencing human or murine KRAS and subjected to migration assays.
(E) DLD-1 and DKO4 cells were transfected as indicated and subjected to migration assays. Migration was normalized to control transfected DKO4 cells.
(F) Panc Tu I cells were transfected as indicated and subjected to migration assays.
(G) A549-luc, DLD-1, and Colo357 cells were subjected to invasion assays.
(legend continued on next page)
Human TRAIL-R2 Drives Cancer Cell Proliferation, Migration, and Invasiveness Humans express two mTRAIL-R homologs, TRAIL-R1 and TRAIL-R2. Therefore, we next tested whether and which of these two receptors could be responsible for the promotion of oncogenic cellular traits. Interestingly, stable RNA interference (RNAi)-mediated suppression of TRAIL-R2, but not TRAIL-R1, in the KRAS-mutated NSCLC cell line A549 led to reduced colony formation in soft agar ( Figure 2A ). In addition, knockdown (KD) of TRAIL-R2 in KRAS-mutated Panc Tu I (pancreas), A549 (lung), and DLD-1 (colon) cells, representing the three most common cancer types with KRAS mutations led to decreased proliferation in two of three cell lines ( Figure 2B ). Irrespective of this mixed response between cell lines, KD of TRAIL-R2 or mTRAIL-R reduced basal migration of KRAS-mutated cell lines further than that of KRAS-WT cells, irrespective of tissue origin (Figures 2C, S1A, and S1B; Table S1 ). Despite detectable expression of both DD-containing TRAIL-Rs ( Figure S1C ), migration was affected only by KD of TRAIL-R2 ( Figure S1D ). Intriguingly, the suppressive effect of KD of TRAIL-R2 on migration was almost identical to that of KD of KRAS ( Figure 2D ). To test whether TRAIL-R2-mediated migration would be responsible for the increased migratory capacity observed in KRASmutated as compared with KRAS-WT cells, we used isogenic colon carcinoma cell lines that contained the oncogenic mutant KRAS (KRAS G13D ) and WT allele (DLD-1) or only the WT allele (DKO4) (Shirasawa et al., 1993) . KD of TRAIL-R2 abrogated the enhanced migratory capacity of KRAS-mutated DLD-1 cells, whereas basal migration of KRAS-WT DKO4 cells remained unaltered ( Figure 2E ) despite expression of comparable levels of TRAIL-R2 and efficient KD ( Figure S1E ). Moreover, TRAIL-R2-mediated migration was ligand dependent as KD of endogenous TRAIL reduced migration to a similar extent as TRAIL-R2 KD alone or the combined KD of both proteins ( Figure 2F ). In addition, TRAIL blockage using TRAIL-R2-Fc similarly inhibited migration ( Figure S1F ). Interestingly, when subjecting native cell lysates to size-exclusion chromatography (SEC), a portion of TRAIL-R2 was present in high molecular weight fractions along with endogenous TRAIL ( Figure S1G ). Furthermore, KD of TRAIL led to a shift of TRAIL-R2 from high molecular weight fractions to the size range of trimerized TRAIL-R2 ( Figure S1H ). Besides affecting migration, TRAIL-R2-KD also blunted invasion to nearly the same low level exhibited by the noninvasive cell line NIH 3T3 ( Figure 2G ). Finally, absence of human TRAIL-R2 or systemic inhibition of TRAIL using TRAIL-R2-Fc treatment also suppressed lung tumor growth (Figures 2H, S1I, and S1J) and PDAC liver metastasis in a previously described PDAC metastasis model (Figures 2I and S1K) (Egberts et al., 2008) . Thus, TRAIL-R2 is the human homolog of mTRAIL-R responsible for stimulating tumor growth, migration, and metastasis.
TRAIL triggers apoptosis through formation of the deathinducing signaling complex (DISC) containing FADD, caspase-8 and caspase-10 and cFLIP (Kischkel et al., 2000 (Kischkel et al., , 2001 Sprick et al., 2000 Sprick et al., , 2002 . Surprisingly, we found that suppression of caspase-8 did not affect migration ( Figure S1L ), and TRAIL-R2 KD still inhibited migration of three independent A549 FADD KO clones ( Figure S1M ). TRAIL-R2-mediated migration therefore does not require the DISC.
To identify the intracellular migration effector domain of TRAIL-R2, we next reconstituted stable TRAIL-R2 KD cells with either full-length TRAIL-R2 or mutants lacking the entire intracellular domain (DICD), the DD (DDD), the short C-terminal domain (DCTD), or the DD and CTD (DDD/CTD) ( Figure 2J ). Expression of the full-length TRAIL-R2, DDD/CTD, or DCTD was sufficient to reconstitute migration ( Figure 2K ). Therefore, the membrane-proximal domain (MPD) of TRAIL-R2, a domain with previously unknown function, is the minimum intracellular domain required to reconstitute migration.
Spontaneous Metastasis in KRAS-Driven PDAC Requires Cancer Cell-Expressed mTRAIL-R Since human TRAIL-R2 was required for migration and invasion besides proliferation (Figure 2 ), we next investigated the role of mTRAIL-R in the metastatic KPC mouse model of PDAC (Hingorani et al., 2005) . Recombination of the floxed mTRAIL-R allele could be detected in the pancreata of KPC-mTRAIL-R FL/FL mice along with remaining floxed alleles due to mosaic expression of Cre ( Figure S2A ). Absence of mTRAIL-R from KPC pancreatic cancer cells increased survival from a median of 112 days in KPC-mTRAIL-R WT/WT mice to 180 days in KPCmTRAIL-R FL/FL mice ( Figure 3A ). As primary tumor size is known to be the main determinant of endpoint in this model, mTRAIL-R FL/FL KPC tumors must have taken longer to reach the same size as WT tumors in order to result in prolonged survival in the absence of mTRAIL-R. Moreover, both groups had equally sized primary tumors at their respective times-of-death ( Figure S2B ) despite the fact that there was considerably more time for tumors to grow in the mTRAIL-R FL/FL group. These results, in conjunction with the results obtained in the KC model ( Figure 1E ), imply that delayed primary tumor growth is a consequence of delayed PanIN formation and that this is responsible for increased survival of KPC mice with conditional mTRAIL-R deletion. When examining animals for presence of distant metastases, we detected liver and lung metastases in a high percentage of KPC-mTRAIL-R WT/WT mice while liver metastases were (H) 2 3 10 6 A549-luc pLKO.1 or shTRAIL-R2 were injected intravenously into SCID beige mice (n = 9 mice per group). Tumor burden was quantified in paraffin sections of H&E-stained lungs by pathological inspection. (I) 1 3 10 6 PancTu-I shCtr (n = 9) or shTRAIL-R2 (n = 8) were orthotopically implanted into pancreata of SCID beige mice. After 10 days, primary tumors were resected, and the number of liver macrometastases was determined. See also Figure S1 and Table S1 .
completely absent and lung metastases present in only two out of eleven mTRAIL-R FL/FL KPC mice ( Figures 3B and 3C ).
To confirm that lung lesions in KPC mice originated from the pancreas, we stained for PDX1, a weakly expressed but specific pancreatic marker, Sp-C, a marker for alveolar type II epithelial cells, and CC10, a specific marker for Clara cells because KRAS-driven lung tumors in mice have previously been shown to be Sp-C positive and CC10 negative (Sotillo et al., 2010) . KPC lung lesions stained positive for PDX1 and negative for Sp-C and CC10 and were therefore of pancreatic origin (Figure 3D ), whereas comparative stainings of primary murine lung cancers from KP mice were positive for Sp-C and negative for CC10 within tumors ( Figure 3E ). Of note, the overall occurrence of metastasis did not correlate with primary tumor size (Figure S2C) . Together, this demonstrates that failure to efficiently metastasize in the absence of mTRAIL-R is not a consequence of delayed primary tumor formation but specifically disabled by absence of mTRAIL-R from KRAS-driven pancreatic cancer. Thus, mTRAIL-R deletion in KRAS-driven PDAC delays primary tumor growth, prolongs survival, and blunts metastasis.
Cell-Autonomous TRAIL-R2 Stimulation Promotes Activation of Promigratory Rac1/PI3K Signaling We noted that TRAIL-R2-KD cells had a more rounded morphology than control cells and lacked lamellipodia (Figure 4A) . Interestingly, the same morphology was described for cells deficient in the small GTPase Rac1 (Steffen et al., 2013) , an important mediator of migration and invasion (Sanz-Moreno and Marshall, 2010) . When testing whether this pathway was affected, we found that Rac1 activity was substantially reduced by TRAIL-R2 KD ( Figure 4B ). Moreover, silencing of Rac1 reduced migration to a similar extent as TRAIL-R2 KD, and no additional reduction was achieved by co-suppression of TRAIL-R2 and Rac1, suggesting that TRAIL-R2 and Rac1 might act sequentially in one pathway ( Figure 4C ). Further substantiating this notion, while suppression of the small GTPase RhoA, known to negatively regulate Rac1 activity via ROCK activation (Sanz-Moreno et al., 2008) , significantly increased migration, this was completely reversed by co-KD of TRAIL-R2 ( Figure S3A ). Intriguingly, overexpressed Rac1 but not dominant negative (dn) Rac1 bound to TRAIL-R2 ( Figure 4D ) and GTP-bound but not GDP-bound Rac1 formed part of a complex with TRAIL-R2 and TRAIL ( Figure 4E ). Rac1 is known to be able to promote both migration and proliferation/tumor growth (Heasman and Ridley, 2008; Myant et al., 2013) . In line with this, pharmacological Rac1 inhibition strongly impaired proliferation only in cell lines in which TRAIL-R2 promoted proliferation ( Figure 4F ). Rac1 activation has been described to be either dependent or independent of phosphoinositide 3-kinase (PI3K) (Lambert et al., 2002; Nimnual et al., 1998) . Therefore, we first interrogated whether KD of PTEN, which counteracts PI3K activity (Ali et al., 1999) , would stimulate PI3K-dependent migration. Indeed, suppression of PTEN strongly induced migration, all of which could be blocked by treatment with the PI3K inhibitor GDC-0941 (Figure 4G) . Furthermore, KD of TRAIL-R2 reduced phosphorylation of AKT in both presence and absence of FADD and was induced by expression of TRAIL-R2 DDD/CTD but not by DICD (Figure 4H ). KRAS requires direct p110a subunit binding to activate PI3K (Gupta et al., 2007) . In order to test whether oncogenic KRAS required TRAIL-R2 for this, we subjected a KRAS-WT cell line with inducible KRAS G13D expression ( Figure S3B ) to TRAIL-R2 or control KD and treatment with either the p110a-(A66) or p110b-specific inhibitor (TGX221). TRAIL-R2-KD did not affect KRAS-mediated pAKT induction that was p110a dependent ( Figure S3C ). PI3K-dependent migration instead required p110b activity ( Figure S3D ). Interestingly, a recent study demonstrated that GTP-bound Rac1 interacts with p110b (Fritsch et al., 2013) , which was also the case in cells using TRAIL-R2 for migration ( Figure S3E ). Importantly, PI3K-dependent migration and increased phosphorylation of AKT could be reversed by co-suppression of either TRAIL-R2 or Rac1 (Figure 4I) . Together, these results place TRAIL-R2 upstream of Rac1 and Rac1 upstream of PI3K activity in the cell migration pathway triggered by endogenous TRAIL/TRAIL-R2. The question remained, however, how oncogenic KRAS allowed for TRAIL-R2-mediated migration. Interestingly, KRASmutated cells are resistant to TRAIL-induced apoptosis through KRAS-mediated ROCK suppression (Hoogwater et al., 2010) . Moreover, Rac1-mediated mesenchymal migration is inhibited by ROCK (Sanz-Moreno et al., 2008) . Based on these findings, we interrogated whether pharmacological ROCK inhibition might be sufficient to release a constraint on Rac1 activation in KRAS-WT cells and thus enable TRAIL-R2-mediated migration. KRASmutated cells showed constitutive suppression of ROCK activity as compared with isogenic WT cells (Hoogwater et al., 2010) ( Figure S3F ). Pharmacological ROCK inhibition using the inhibitor Y27632 was indeed sufficient to induce TRAIL-R2-mediated migration in KRAS-WT cells ( Figure S3G ). Moreover, this same ROCK-inhibitor-induced migration that was dependent on TRAIL-R2 could be reversed by PI3K inhibition ( Figure S3H ) demonstrating that ROCK inhibition, mediated by oncogenic KRAS, removes a constraint on TRAIL-R2-mediated migration. Thus, we propose a model in which endogenous TRAIL/TRAIL-R2 promote a Rac1/PI3K signaling axis in KRAS-mutated cells, which in turn drives proliferation and migration ( Figure 4J ).
mTRAIL-R Activates Rac1 in KPC-Derived Tumors In Vivo
Fö rster resonance energy transfer (FRET) is a highly sensitive method that has been used widely to determine RhoGTPase activity in real time (Aoki and Matsuda, 2009; Hodgson et al., 2010; Kraynov et al., 2000) . In order to monitor Rac1 activity, the ''Raichu'' (Ras superfamily and interacting protein chimeric unit) Rac-FRET probe has been developed in which Rac1 coupled to a fluorescent protein is fused to the fluorophor-coupled CRIB domain of the RacGTP-binding protein Pak1 (Itoh et al., 2002) ( Figure S4A ). To test whether mTRAIL-R would affect RaichuRac activity, we generated stable mTRAIL-R KD lines using two different shRNA sequences (23 and 25) from previously generated KPC-derived cell lines (Morton et al., 2010) . These cells were subsequently transfected with a Rac-FRET probe suitable for intravital imaging and transplanted into Nude mice ( Figure S4B ). Subsequently, in vivo Rac1 activity was determined by intravital microscopy using cutaneous optical imaging windows (Ritsma et al., 2013) . Strikingly, absence of mTRAIL-R from KPC subcutaneous tumors resulted in a significant increase in average fluorescent lifetime, corresponding to decreased Rac1 activity in both stable KD clones in live KPC tumors in vivo (Figures 5A and 5B) . Moreover, blocking mTRAIL by systemic treatment with mTRAIL-R-Fc also strongly inhibited Rac1 activity in subcutaneous KPC tumors, providing evidence for endogenous TRAIL as stimulus for mTRAIL-R-mediated Rac1 activation in vivo ( Figure 5C ). Since systemic blockade of TRAIL can equally block host and cancer cell-derived TRAIL, we tested whether KPC-derived Rac-FRET cells were in principle self-sufficient in producing TRAIL to stimulate mTRAIL-R in vitro. Indeed, in vitro treatment of KPC-Rac-FRET cells with mTRAIL-R-Fc was sufficient to inhibit Rac1 activity ( Figure 5D ). Together, these data show that KRAS-mutated KPC-derived tumors use the cancer cell-expressed mTRAIL/mTRAIL-R system to promote Rac1 activity in vivo.
High TRAIL-R2 Expression Correlates with Parameters of Malignancy in Patients with KRAS-Mutated Cancers
To evaluate the relevance of TRAIL-R2 in human cancers with KRAS mutations, we analyzed TRAIL-R1 and TRAIL-R2 expression in primary PDAC resected from patients. In a cohort of 95 tumors, 84% of PDAC highly expressed TRAIL-R2, whereas expression of TRAIL-R1 was high in only 9% of PDAC with all other tumors being either negative or low for TRAIL-R1 expression ( Figure 6A ). Of note, it was previously shown that only TRAIL-R1 is used for apoptosis induction in PDAC cell lines (Lemke et al., 2010) , suggesting that human PDAC might select for expression of TRAIL-R2 and against that of TRAIL-R1. Importantly, when analyzing another PDAC cohort (n = 106) with additional clinical information, high TRAIL-R2 expression correlated with lymph vessel invasion of tumors ( Figure 6B) .
Metastases from PDAC patients are rarely resected and thus seldom available for histological analysis. We therefore analyzed TRAIL-R1 and TRAIL-R2 expression in lung metastases of a cohort of 36 CRC patients of which 18 carried oncogenic KRAS mutations and 18 were KRAS-WT. In contrast to the PDAC cohorts, TRAIL-R1 and TRAIL-R2 were both expressed at detectable levels in lung metastases of KRAS-mutated and KRAS-WT CRC patients ( Figure 6C ), indicating that a selection for expression of one versus the other receptor had not taken place in CRC. Strikingly, however, low expression of TRAIL-R2, but not TRAIL-R1, correlated with prolonged metastasis-free survival of patients with KRAS mutant CRC ( Figure 6D ) but not (E) Endogenous Rac1 in A549-luc cell lysates was loaded with GDP/GTPgS in vitro, and GTP-bound Rac1 was isolated using PAK1-RBD beads and analyzed by western blot.
(legend continued on next page) in patients with WT KRAS CRC ( Figure 6E ). Together, these data support a proinvasive and prometastatic role of TRAIL-R2 in KRAS-mutated human cancers.
DISCUSSION
Treatment with recombinant TRAIL was selectively able to kill tumor cells in vivo without toxicity (Ashkenazi et al., 1999; Walczak et al., 1999) . It is therefore counterintuitive that apoptosisinducing TRAIL-Rs are highly expressed in many cancers (Daniels et al., 2005; Elrod et al., 2010; Ganten et al., 2009; Macher-Goeppinger et al., 2009; Ozawa et al., 2001; Sanlioglu et al., 2007; Spierings et al., 2003) . We show here that cancer cell-expressed mTRAIL-R promotes cancer progression, invasion, and metastasis in KRASdriven autochthonous mouse models of NSCLC and PDAC. Constitutive signaling from TRAIL-R2 promotes activation of a Rac1/PI3K signaling axis that increases migration and invasion in a cancer cell-autonomous manner. Moreover, we provide in vivo evidence that endogenous mTRAIL and mTRAIL-R activate Rac1 in KPC tumor cells. Interestingly, Rac1 has (F) The indicated cell lines were subjected to KDs or NSC23766 treatment (100 mM) for 72 hr and then BrdU proliferation assays. (G) A549-luc cells were subjected to the indicated KDs and migration assays or western blot analysis in the presence or absence of GDC-0941 (1 mM). been shown to be required for early metaplastic changes in autochthonous KRAS-driven NSCLC (Kissil et al., 2007) and PanIN formation (Heid et al., 2011) in line with our finding that mTRAIL-R promotes Rac1 activity in both cancers. Moreover, elevated Rac1 activity has been measured in KPC tumors as compared with normal pancreatic tissue (Johnsson et al., 2014) . Our results now show that blocking the endogenous TRAIL/mTRAIL-R interaction reduces Rac1 activation, delays tumor growth, and blunts metastasis. Since TRAIL-and TRAIL-Rdeficient mice do not show a gross phenotype (Cretney et al., 2002; Finnberg et al., 2008; Grosse-Wilde et al., 2008) , therapeutic inhibition of TRAIL or TRAIL-R2 is unlikely to cause toxicity and might therefore be advantageous over other therapeutic strategies targeting KRAS-effector pathways.
Mechanistically, we identify that TRAIL-R2 mediates migration via the MPD of TRAIL-R2. Intriguingly, human TRAIL-R2 and mTRAIL-R share a part of the MPD that is not present in the TRAIL-R1 MPD. It will therefore be interesting to delineate the precise molecular pathway that is triggered from this domain. This will, however, require more sensitive experimental approaches, as the endogenous TRAIL/TRAIL-R complex is not abundant enough for proteomic analysis (data not shown).
Recently, endogenous TRAIL-R2 has been shown to promote proliferation of pancreatic cancer cell lines via inhibition of let-7 maturation in the nucleus in a ligand-independent manner (Haselmann et al., 2014) . We find endogenous TRAIL bound to TRAIL-R2 associated with the active form of Rac1, which is mainly found in association with the plasma membrane, suggesting that the TRAIL/TRAIL-R2-mediated Rac1 activation occurs at the plasma membrane.
We previously showed in an autochthonous model of skin cancer formation, driven by oncogenic mutation of Hras (Balmain et al., 1984) , that constitutive mTRAIL-R deficiency suppressed metastasis (Grosse-Wilde et al., 2008) . This antimetastatic role of the mTRAIL-R seems to contradict the findings reported here. However, we could confirm an antimetastatic role for TRAIL-R1 in patients with KRAS-WT CRC as high expression of this receptor correlated with prolonged metastasis-free survival. In contrast to this, high TRAIL-R2 expression in KRAS-mutated CRC correlated with shortened metastasis-free survival, suggesting that the role of TRAIL-R2 and TRAIL-R1 as well as mTRAIL-R is dependent on the oncogenic context. Accordingly, TRAIL-R2 suppression does not affect migration in KRAS-WT or HRAS-mutated cells (data not shown). Furthermore, we identify ROCK inhibition to be the prerequisite for TRAIL/TRAIL-R2-mediated migration. In addition, induction of oncogenic HRAS expression, which did not allow for TRAIL-R2-mediated migration, also did not inhibit ROCK activity (data not shown). It will therefore be interesting to investigate whether other pathways that inhibit ROCK might utilize TRAIL/TRAIL-R2 similarly.
In conclusion, we identify cancer cell endogenous TRAIL-R2/ mTRAIL-R stimulation as a promoter of cancer progression, invasion, and metastasis of KRAS-mutated cancers offering an explanation as to why these cancers not only retain TRAIL-R expression but also frequently upregulate it. On the basis of these results, it is tempting to speculate whether patients with KRAS-mutated cancers that are resistant to apoptosis induction might benefit from inhibition of the constitutive TRAIL/TRAIL-R2 interaction.
EXPERIMENTAL PROCEDURES
Animal Models A549 Lung Tumors Twelve-week-old female Fox Chase SCID Beige mice (Charles River) were injected with 2 3 10 6 A549-luc vector control or shTRAIL-R2 cells via the lateral tail vein. Starting on day 1 after cell injection, all mice were imaged weekly for bioluminescence using the IVIS Spectrum at 1-min exposure time (Caliper Life Science). Photons per second (Photon Flux) were quantified using IVIS Spectrum software.
Orthotopic PDAC Metastasis
Experiments were carried out in female SCID beige mice (Charles River). 1 3 10 6 PancTu-I shCtr or shTRAIL-R2 were orthotopically transplanted into the pancreas, and tumors were resected 10 days later as previously described (Egberts et al., 2008) . Animals were sacrificed and organs preserved at day 26 postresection.
, and PDX-1-Cre mice on C57BL/6 background were kindly provided by D. Tuveson, and mTRAIL-R FL/FL mice on C57BL/6 background were previously generated by our laboratory (GrosseWilde et al., 2008) .
KP-mTRAIL-R Mice
Mixed-gender Kras
G12D
;p53
R172H
;mTRAIL-R WT/WT or FL/FL mice were intranasally infected with a single dose of 2 3 10 7 pfu Ad-Cre to induce tumors.
Rac-FRET Tumors
After transfection of KPC shCtr and shTRAIL-R2 cell lines with a GFP and RFP version of the Rac-FRET reporter (Mack et al., 2012) and selection for stable expression with neomycin, 2 3 10 6 cells were subcutaneously injected into the flanks of nude mice. Following primary tumor development of 7 to 8 days, a cutaneous version of the abdominal imaging window described previously (Ritsma et al., 2013) was surgically implanted on top of the tumors under isoflurane. Mice were subsequently imaged for up to 2 hr on a 37 C heated stage under isoflurane, using the described multiphoton TCSPC system. For treatment with mTRAIL-R-Fc, mice were imaged prior to and 1 hr after intraperitoneal injection of either PBS or 0.5 mg per mouse of mTRAIL-R-Fc. The orthotopic PDAC metastasis experiment was conducted in accordance with the Office of Laboratory Animal Welfare and the German Federal Animal Protection Laws and approved by the Institutional Animal Care and Use Committees of the University of Kiel. The Rac-FRET experiments were conducted under an appropriate animal project license approved by the UK home office and in accordance with the Animal Welfare and Experimental Ethics Committee at the Beatson Institute of Cancer Research. All other animal experiments were conducted under an appropriate animal project license approved by the UK home office, in accordance with the revised (2013) Animals (Scientific Procedures) Act (ASPA) and the institutional guidelines of the UCL Cancer Institute.
siRNA-Mediated KD KD experiments were performed by transient transfection of siRNA smartpools or single siRNA sequences to silence the indicated proteins or RISC-free control using Dharmafect I (Dharmacon) following the instruction manual. All cell lines were incubated for 48 hr to achieve sufficient KD efficiency. See Supplemental Experimental Procedures for detailed description.
Migration/Invasion Assays
Migration/Invasion assays were performed using the xCELLigence System (Cambridge Bioscience). See Supplemental Experimental Procedures for detailed description.
Patient Cohorts
Informed consent was obtained from all individuals, and use of samples for histology was approved by the ethics committees of the University of Heidelberg (PDAC cohort 1), Kiel (PDAC cohort 2), and of the Medical University of Vienna (CRC lung metastasis cohort). See Supplemental Experimental Procedures for detailed description.
Statistical Analysis
Data were analyzed using GraphPad Prism 5 software (GraphPad Software). Results are expressed as means ± SEM. Statistical significance between groups was determined using Student's t test and/or one-way ANOVA, followed by the Bonferroni post-test. A p value of < 0.05 was considered significant: **p < 0.01 and ***p < 0.001 (ns = nonsignificant). ) H322 cells were treated with the indicated concentrations of Doxycycline (Dox) for 48 hr, serum starved for 4 hr and then subjected to Western blotting. (C) H322 iKRAS G13D cells were subjected to the indicated knockdowns, after 24 hr medium or 250 ng/ml Doxycycline were added for additional 48 hr. Cells were then serum starved for 4 hr in the presence of the indicated inhibitors (both 1 µM) and subjected to Western blotting. (D) A549 cells were subjected to the indicated knockdowns for 48 hr and then left to migrate in the presence or absence of the indicated inhibitors (both 1 µM). (E) Endogenous Rac1 in A549 cell lysates was loaded with GDP/GTPγS in vitro, and GTPbound Rac1 was isolated using PAK1-RBD beads. (F) The indicated cell lines were left untreated or treated with 10 µM Y27632 for 2 hr and subjected to Western blotting. (G) KRAS-WT H522 cells were subjected to the indicated KD, treated with DMSO or 10 µM Y27632 and subjected to migration assays. 
SUPPLEMENTAL INFORMATION
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES Reagents
Antibodies: HS101, HS201, H301 and H402 were used for surface staining of TRAIL-R1 to TRAIL-R4 and α-TRAIL-R1 (TR1.02; mIgG2b), α-TRAIL-R2 (TR2.21; mIgG1) for immunohistochemistry, all are available from Adipogen. α-FADD was purchased from BD Bioscience, α-KRAS from Santa Cruz, α-β-Actin from Sigma, α-Rac1 and α-Rho from Millipore, α-TRAIL-R2 from Cell Signaling for knockdown detection, from ProSci for SEC and from ENZO (anti N-terminal) for detection of C-terminal deletion mutants, α-Caspase-8 as described (Scaffidi et al., 1997) , α-TRAIL from Alexis and α-TRAIL-R1 was purchased from ProSci. α-pAKT and AKT were purchased from Cell Signaling and α-PTEN from Santa Cruz.
Recombinant proteins: DR6-Fc, TRAIL-R2-Fc, mTRAIL-R-Fc and TNF-R2-Fc were purified from supernatants of transfected HEK293T cells via protein A columns (GE Healthcare) and used at 100 µg/ml, iz-TRAIL was produced in E. coli, purified as described previously (Ganten et al., 2006) , iz-TRAIL was LPS-free after purification as tested by Limulus amebocyte lysate (LAL) assay (LONZA). GDC-0941, A66 and TGX221 were purchased from Selleck Chemicals.
NSC23766 and Y27632 were purchased from Calbiochem. All siRNA sequences were purchased from Dharmacon and tested using single sequences or the mixed pool: siControl (siGENOME RISC-Free Control siRNA, D-001220-01-20), siTRAIL-R1 (set of 4 sequences MU-008090-02-0002); siTRAIL-R2 (set of 4 sequences MU-004448-00-0005); simTRAIL-R (set of 4 sequences L-050949-00-0005); si human KRAS (set of 4 sequences L-005069-00-0005); si mouse KRAS (set of 4 sequences LU-043846-01-0002); siTRAIL (set of 4 sequences LU-011524-00-0002); siCaspase 8 (set of 4 sequences LU-011524-00-0002); siRac1 (set of 4 sequences LU-003560-00-0002); siRhoA (set of 4 sequences LU-003860-00-0002); siPTEN (set of 4 sequences LU-003023-00-0002). 
Cell lines
Migration assays
Migration assays were performed using the xCELLigence System (Acea Biosciences, Inc.) that uses specially designed microtiter plates containing gold microelectrodes to measure electrical impedance of cells adhering to electrodes in real time. Increased impedance of background control wells was subtracted from all other values, the increase in electrical impedance/migration of control siRNA-transfected/control vector-infected cells was then defined as 100% migration and relative migration of all other transfected samples was calculated as compared to control-transfected cells, accordingly. Migration plates (CIM 16) are based on the Boyden chamber principle, the lower surface of the filter is covered with microelectrodes measuring cells that have migrated through the pores and adhere to the lower surface of the filter in real-time. Briefly, the lower chambers of a CIM 16 plate were filled with medium containing 2% FCS as chemoattractant, the upper part was assembled and 30 µl of FCS-free medium was added to the top wells. The plate was then equilibrated at 5% CO 2 and 37°C for 1 hr. Cells were trypsinized and washed three times in FCS-free medium. Then, 8 x 10 5 cells were resuspended in 1 ml FCS-free medium and 100 µl cell suspension was added to each well after a background measurement without cells was performed. Four wells without cells (FCS-free medium only) were included as assay background control. Cells were left to settle in the top well of the plates at room temperature for 30 minutes and then plates were returned to the RTCA-DP xCELLigence system and impedance measurements were taken every minute. Cells that had been transfected with siRNA were left to migrate for a total of 6 hr.
Invasion assays
Invasion assays were performed using the xCELLigence System (Acea Biosciences, Inc.) that measures cell impedance in real-time (see Migration assay). In this assay, E-plates were used which do not follow a Boyden chamber principle but are regular wells (16-wells, each with the size of a 96-well) that contain gold electrodes at the bottom of the well. Wells were coated with 30 µl of 1:10-diluted Matrigel (BD) and left to set in the incubator for 1 hr.
Importantly, matrigel was diluted in medium containing 10% FCS to promote invasion. In the meantime cells were prepared as described for the migration assay. Again, before adding washed cells to the well, a background measurement was taken. After adding cells, they were left for 30 minutes at room temperature to settle. Wells without cells and the noninvasive cell line NIH3T3 were included as controls in each experiment. E-plates were then returned to the RTCA-DP xCELLigence system to take measurements every minute for a total of 6 hr. Cell Index measurements increase as a function of cells that have passed through the matrigel and have reached the electrodes. Background of wells without cells was subtracted and control transfected cells were set to 100% migration and relative migration of TRAIL-R2 knockdown cells and NIH3T3 was calculated accordingly. Subsequently, the matrigel layer was removed and cells adhering to electrodes were stained by crystal violet and washed with PBS.
Soft agar assays
Growth of cells in soft agar was determined using the Cell Transformation Detection Assay 
Western blot analysis
Cells were treated as indicated and then lyzed in IP-lysis buffer (30 mM Tris-HCl [pH 7.4], 120 mM NaCl, 2 mM EDTA, 2 mM KCl, 1% Triton X-100, 1× COMPLETE protease-inhibitor cocktail) at 4°C for 30 minutes. Proteins were separated by SDS-PAGE (NuPAGE) and analyzed by Western blotting. Membranes were stripped with 50 mM glycine (pH 2.3) before reprobing with other antibodies.
Rac1 pulldown assays
2.5 x 10 6 cells were seeded into 10 cm dishes. The next day, cells were incubated with and without 100 ng/ml iz-TRAIL. Cell lysis and Rac1 pulldown was performed using a Rac1-pulldown kit (Millipore) according to the manufacturer's instructions. Proteins were separated by SDS-PAGE (NuPAGE) and analyzed by Western blotting.
Generation of cells expressing shRNA targeting TRAIL-R1, TRAIL-R2 and mTRAIL-R
A549-luc/DLD-1 cells were seeded at 5 x 10 5 cells into 25 cm 2 flasks. The following day, they were infected with 1:2 medium-diluted lentivirus supernatant containing sequences for either the vector (plKO.1) or five different shRNA sequences for human TRAIL-R1 or human TRAIL-R2, respectively. All sequences were purchased from Sigma. After 48 hr incubation with the virus, cells were subjected to selection with 2 µg/ml puromycin for 2 weeks.
Subsequently, selected cells were subjected to Western blot to determine levels of TRAIL-R For stable knockdown of TRAIL-R2 or non-silencing control in PancTu I cells, the GIPZ lentiviral shRNAmir vector system was used (both plasmids were from Open Biosystems;
Clone ID: V2LHS_16711) and selected with puromycin (1 µg/ml). Stable KD of mTRAIL-R in KPC cells was achieved using either sh23 (TRCN0000012323) or sh25 (TRCN0000012325), both purchased from Sigma. The lentiviral vector pLKO.1 was used as control. 
Generation of FADD KO cell lines
Confocal analysis
Cells were seeded on poly-Lysine-coated microscopic coverslips at 2.5 x 10 4 cells/24-well.
The following day, cells were treated as indicated, then fixed for 10 minutes in 5%
formaldehyde, subsequently permeabilized (in PBS containing 0.02% Triton-X 100 and 1%
BSA for 5 minutes) and blocked (in 1% BSA for 1 hr). Texas-Red coupled Phalloidin (Invitrogen, Molecular Probes) was used at 5 µl/200 µl blocking buffer as suggested by the manufacturer and incubated for 30 minutes at RT in the dark. Subsequently, the cells were washed three times with PBS, and Phalloidin-stained coverslips were mounted in DAPI (ProLong® Golds antifade reagent with DAPI, Invitrogen). Images were acquired at x400 magnification using a confocal microscope and software (Leica).
Size exclusion chromatography (SEC)
5 x 10 6 cells were lysed in 240 µl of IP-lysis buffer (30 mM Tris-HCl [pH 7.4], 120 mM NaCl, 2 mM EDTA, 2 mM KCl, 1% Triton X-100, 1× COMPLETE protease-inhibitor cocktail, 10 mM
MgCl 2 ) at 4°C for 20 minutes. Subsequently, lysates were cleared by centrifugation and additional centrifugal spin filtration (0.2 µm). At this point lysates were either stored at -80°C or fractionated using the Superose™ 6 PC 3.2/30 (GE Healthcare). Briefly, the column was equilibrated with 2 column volumes (2x 2,4 ml) of running buffer (20 mM HEPES, 120 mM NaCl, 2 mM EDTA, 2 mM KCl, 5% [w/v] sucrose, 1% Triton X-100, [pH 7.5]). Lysates were then injected and collected in 50 µl fractions. 12 µl of fractions 9-32 were analyzed by Western blotting.
BrdU Proliferation Assay
24 hr after cells had been subjected to transient knockdowns as described in Experimental procedures, BrdU stock (Cell proliferation assay kit, Calbiochem) was added at a dilution of 1:2000 in medium and incubated for another 24 hr. Then, the BrdU proliferation assay was performed according to the manufacturer's instructions.
Cell viability assays
Cell viability was determined using the Cell Titer Glo assay (Promega) according to the manufacturer's instructions or the MTT assay when indicated.
DISC Analysis
We performed ligand affinity precipitations using Flag-tagged TRAIL in combination with M2 beads (Sigma). Cells were incubated for 10 minutes at 37°C in the presence or absence of 1 µg/ml Flag-izTRAIL as described previously (Walczak and Haas, 2008) .
Re-expression of wild type and mutant versions of TRAIL-R2
A549-luc pLKO.1 and shTRAIL-R2 (targeting the 3'UTR) cells were transfected with either 
Anoikis Assay
Cells were washed with DPBS, trypsinized and seeded at 1.5 x 10 5 cells/well in 1 ml into Corning® Ultra-Low Attachment 24-well plates that are coated with a hydrophilic hydrogel preventing cell adhesion. After 72 hr incubation, cells were spun down, resuspended in propidium iodide (PI) buffer and dead cells were determined as PI-positive cells by flow cytometry.
Luciferase Assay
Stable A549-luc knockdown cells were seeded at the indicated numbers in 96-well plates.
The following day, medium was removed and cells were permeabilized with 30 µl of Permeabilization Buffer (eBioscience) for 15 minutes. Subsequently, 30 µl Firefly luciferincontaining buffer (Luciferase Assay buffer) was added and incubated for 10 minutes. The relative luminescence was determined using a Mithras plate reader.
Immunohistochemistry (IHC)/Immunofluorescence (IF)
For preparation of lung tissue sections, mice were sacrificed 3.5 weeks after cell injection were from Dako, Glostrup, Denmark.
Histological Quantifications
Lung metastasis burden (xenograft) was quantified by determining the percentage of lung replaced by tumor cells or by counting all nodules within a central 50x microscopic field, the number of PanIN lesions was counted in sections of H&E-stained whole murine pancreases, presence of liver and lung metastases was judged by inspecting two central serial sections from liver and lung, respectively, for all groups. All histopathological analyses were performed by an experienced pathologist (M. A. E.-B.) who was blinded to the study design.
FLIM-FRET Microscopy
Frequency domain FLIM in vitro: FRET was measured using frequency domain Fluorescence lifetime microscopy (FLIM) in vitro as described previously by Mack et al.. Briefly, a Nikon
Eclipse TE 2000-U microscope with a Lambert Instruments LIFA attachment was used with a Yokogawa CSU 22 confocal scanner unit and a ×100 1.4 NA oil objective. A 488 nm laser modulated at 40 mHz (60 mW, Deepstar, Omicron) was used together with a GFP-filterblock set (470/40X, T495LP, 525/50M) to detect GFP emission. Erythrosin B (1 mg/ml) was used as a reference standard (at 0.086 ns). The donor lifetime was analyzed by manually drawing regions of interest (ROIs) around whole cell membranes using the FLIM software (Version 1.2.12, Lambert Instruments).
Multiphoton TCSPC FLIM in vivo: Intravital imaging was performed as described previously (Nobis et al., 2013) within the first year. Due to missing follow-up data and patient tissue that did not stain overall, 36 patient tissues entered staining procedures. TRAIL-R1 and TRAIL-R2 were stained as described for the other patient cohorts and their expression levels were quantified by an H-score. In each specimen five randomly selected tumor-containing regions were analyzed.
Intensity score from 0-3 and proportion of the tumor stained with a given intensity was recorded as 10% increments within a range of 0-100. The final H-score (range 0-300) was obtained by adding the sum of scores obtained for each intensity and proportion of area stained. For both TRAIL-Rs, low versus high expression was defined as below or above the median H-score, i. e. for TRAIL-R1, low expression was determined as below an H-score of 150 and for TRAIL-R2, below or above the median H-score of 36.
